Re­silience moves Cana­di­an site in­to plas­ma ther­a­pies, as it signs deal with Take­da

Re­silience has land­ed an­oth­er part­ner in its quest to be­come the Ama­zon Web Ser­vices of drug man­u­fac­tur­ing, and it will use its Cana­di­an foot­print to do so.

The Bob Nelsen start­up has es­tab­lished a part­ner­ship with Take­da’s plas­ma-de­rived ther­a­pies busi­ness unit to de­vel­op and man­u­fac­ture sev­er­al prod­ucts in its port­fo­lio out of its Mis­sis­sauga, On­tario site. That site boasts 136,000 square feet, and can pro­vide an­a­lyt­i­cal de­vel­op­ment, scale up, drug sub­stance, prod­uct and fill-fin­ish man­u­fac­tur­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER